Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MSFT$554.19+35.02(+6.72%)UK Stocks-Factors to watch on November 512:52:05 AM ETMSFT$554.19+35.02(+6.72%)UPDATE 1-Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:44:24 AM ETBRK.A$869,300.76+32,855.63(+3.93%)Berkshire Hathaway: The Easy Re-Rating Is Gone12:39:39 AM ETMSFT$554.19+35.02(+6.72%)Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:11:41 AM ETMSFT$554.19+35.02(+6.72%)BRIEF-Microsoft Rejects Multibillion-Dollar AI Deal With UK's Nscale - FT12:11:33 AM ETMSFT$554.19+35.02(+6.72%)Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:09:40 AM ETTM$205.56+6.45(+3.34%)Toyota profit surges 34%, first rise in six quarters12:02:07 AM ETC$124.58+1.89(+1.54%)UPDATE 1-Oil falls for a fourth day on expectations for lower risk of Iran war escalation11:59:47 PM ETQCOM$160.25+8.76(+5.33%)SpaceX Makes Its Biggest Move Yet Against Telecom Giants With Qualcomm 5G Deal: Elon Musk Hails QCOM's Technology, Calls It 'Excellent'11:59:02 PM ETMCD$278.93+17.15(+6.52%)McDonald's: 3 Key Takeaways for Long-Term Investors11:46:01 PM ETQCOM$160.25+8.76(+5.33%)SpaceX Just Picked Qualcomm for Its Own 5G Network. I Still See the Stock as a Hold.11:41:01 PM ETIONQ$29.52-0.48(-1.60%)IonQ vs. SoundHound AI: Which Technology Stock Is a Better Buy for 2027?11:30:01 PM ETQCOM$160.25+8.76(+5.33%)Qualcomm Q4 Earnings Call Highlights11:27:00 PM ETAMD$485.27+4.95(+1.02%)AMD Stock Jumped After Its Report. I'd Wait for a Lower Price to Buy.11:17:01 PM ETGOOG$288.55+9.01(+3.24%)Google expands voluntary buyouts to 5 countries as AI spending fuels cost cuts11:16:50 PM ETSHOP$153.05+10.32(+7.23%)Shopify: 3 Key Takeaways for Long-Term Investors10:59:40 PM ETMCD$278.93+17.15(+6.52%)Why McDonald's Stock Popped Today10:45:31 PM ETMETA$630.20+8.87(+1.43%)Meta President Says Midterm Results Will Make Building Data Centers Harder10:11:00 PM ETPANW$348.32-2.07(-0.59%)BRIEF-Palo Alto Networks In Talks To Pay $500 Million For AI Security Startup Clutch Security - The Information9:57:31 PM ETMSFT$554.19+35.02(+6.72%)US STOCKS-Wall Street ends higher after Democrats win Congress; data center stocks tumble9:41:58 PM ETASML$1,479.73-72.05(-4.64%)ASML vs. Marvell Technology: Which Artificial Intelligence Stock Is a Better Buy Going into 2027?9:33:56 PM ETABT$115.40+6.10(+5.58%)DIARY-India economic, corporate events on November 59:00:32 PM ETNVO$41.87+1.67(+4.15%)Novo Nordisk: 3 Key Takeaways for Long-Term Investors8:55:55 PM ETAAPL$350.78+17.87(+5.39%)Apple is reportedly cutting budgets for its internal AI usage8:26:22 PM ET

PGEN · NASDAQ

Precigen, Inc.

$4.95 +0.11 (+2.04%)

Company overview

Precigen, Inc. discovers and develops next-generation gene and cellular therapies in the United States. It also provides disease-modifying therapeutics, genetically engineered swine for regenerative medicine applications, and reproductive and embryo transfer technologies. In addition, the company offers the UltraVector platform, which incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which break and rejoin DNA at specific sequences; the AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis, a food-grade bacterium.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.8B
Employees
143
Headquarters
Germantown, MD
Website
precigen.com
CEO
Helen Sabzevari
Listed
August 8, 2013
P/E
-3.86
Dividend yield
0.00%

Company financials

Revenue
$31.6M
Gross profit
$23.9M
Operating income
-$93.9M
EBITDA
-$86.3M
Net income
-$204M
EPS
-$1.28
Total assets
$139M
Total debt
$98.3M
Gross margin
75.63%
Net margin
-646.99%
Earnings yield
-25.89%

Revenue segmentation

By product (FY 2024)
By region (FY 2024)

No annual geographic segmentation.

Showing FY 2024

Price chart

3.294.776.257.729.20
PGEN 1D NASDAQ O5.31H5.34L4.73C5.06-0.20 (-3.71%)Vol9.28M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
PGENPrecigen, Inc. Stock news Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates Zacks Investment Research
PGENPrecigen, Inc. Press release Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance PR Newswire
PGENPrecigen, Inc. Stock news Inovio: Upgrading To 'Buy' On Voceryq Accelerated Approval RRP And Competitive Advantages Seeking Alpha
PGENPrecigen, Inc. Stock news Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect? Zacks Investment Research
PGENPrecigen, Inc. Stock news Kosmos Energy Posts Downbeat Q3 Results, Joins Once Upon A Farm And Other Big Stocks Moving Lower In Monday's Pre-Market Session Benzinga
PGENPrecigen, Inc. Press release Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4 Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medici… PR Newswire
PGENPrecigen, Inc. Stock news Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis Defense World
PGENPrecigen, Inc. Stock news Constellation Brands, Caribou Biosciences And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session Benzinga
PGENPrecigen, Inc. Stock news PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know Zacks Investment Research
PGENPrecigen, Inc. Stock news 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike Zacks Investment Research
PGENPrecigen, Inc. Stock news Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? Zacks Investment Research
PGENPrecigen, Inc. Stock news PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? Zacks Investment Research
PGENPrecigen, Inc. Stock news Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect Seeking Alpha
PGENPrecigen, Inc. Stock news This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Benzinga
PGENPrecigen, Inc. Stock news Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos? Zacks Investment Research
PGENPrecigen, Inc. Press release Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform PR Newswire
PGENPrecigen, Inc. Stock news Head-To-Head Comparison: Precigen (NASDAQ:PGEN) and Celldex Therapeutics (NASDAQ:CLDX) Defense World
PGENPrecigen, Inc. Stock news Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock? Zacks Investment Research
PGENPrecigen, Inc. Stock news Can Papzimeos Drive Precigen's Growth Through the Rest of 2026? Zacks Investment Research
PGENPrecigen, Inc. Stock news 5 Biotech Stocks Worth Adding to Your Portfolio Now Zacks Investment Research
See more
FAQ

Questions about Precigen, Inc.

What does Precigen, Inc. do?
Precigen, Inc. discovers and develops next-generation gene and cellular therapies in the United States. It also provides disease-modifying therapeutics, genetically engineered swine for regenerative medicine applications, and reproductive and embryo transfer technologies. In addition, the company offers the UltraVector platform, which incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which break and rejoin DNA at specific sequences; the AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis, a food-grade bacterium.
What is PGEN's market cap?
Precigen, Inc. (PGEN) is a listed stock with a live quote. The latest market cap on this page is $1.8B.
Where is Precigen, Inc. headquartered?
Precigen, Inc. is headquartered in Germantown, MD.
How do I get PGEN news from the API?
Call GET /v1/news?tickers=PGEN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does PGEN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PGEN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the PGEN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs